欢迎光临源叶生物,登录 | 注册 |
当前位置: 首页 > 小分子抑制剂 > DNADamage/DNARepair > GSK0660

浏览历史

S81673

GSK0660

源叶(MedMol) 99%
  • 英文名:
  • GSK0660
  • 别名:
  • CAS号:
  • 1014691-61-2
  • 分子式:
  • C19H18N2O5S2
  • 分子量:
  • 418.4866
  • 核磁/质谱:
品牌货号产品规格价格(RMB) 库存(上海) 北京 武汉 南京 数量计量单位 加入购物车...
源叶(MedMol) S81673-1mg 99% ¥216.00元 5 - - - EA 加入购物车
源叶(MedMol) S81673-2mg 99% ¥304.00元 7 - - - EA 加入购物车
源叶(MedMol) S81673-5mg 99% ¥520.00元 6 - - - EA 加入购物车
源叶(MedMol) S81673-10mg 99% ¥800.00元 6 - - - EA 加入购物车
源叶(MedMol) S81673-25mg 99% ¥1480.00元 5 - - - EA 加入购物车
源叶(MedMol) S81673-50mg 99% ¥2880.00元 预计交期:2-3天 - - - EA 加入购物车
源叶(MedMol) S81673-100mg 99% ¥5200.00元 预计交期:2-3天 - - - EA 加入购物车
大包装询价

提交您的电话号码并同意《个人信息授权与保护申明》,到货后将短信提示。
提交

产品介绍

参考文献

质检证书(COA)

摩尔浓度计算器

相关产品

  • 提示:详情请下载说明书。
  • 产品描述: GSK0660是有效的PPARβ/δ拮抗剂,pIC50为6.8。在浓度高达近于10 μM时,对PPARα和PPARγ没有活性
  • 靶点: PPAR-β/δ(binding assay):155 nM;PPAR
  • 体外研究:
    GSK0660 inhibits HRMEC (human retinal microvascular endothelial cells) proliferation and differentiation
  • 体内研究:
    GSK0660 is rapidly cleared and does not accumulate in the blood in vivo[1]. GSK0660 is efficacious against retinal NV when administered by IVIT or IP injection. Intravitreal injection has the advantages of producing high levels of drug at active sites of neovascular disease, but deleterious side effects are associated with this route of drug administration, including endophthalmitis, cataractogenesis, and glaucoma. Systemic administration could avoid these side effects, but it is hampered by the need for repeated dosing to obtain target concentrations of active drug in diseased tissues. It also needlessly exposes disease-free organs and tissues to active drug
  • 细胞实验: Cell lines: HRMECs Concentrations: 0.01, 0.1, or 1.0 μM Incubation Time: 6 h Method: HRMECs were seeded in six-well plates at 2 × 105 cells/well and maintained under standard tissue culture conditions. At 80% confluency, the cells were serum starved for 12 hours, then treated on a background of 0.5% serum-containing vehicle (0.1% DMSO) or PPAR-β/δ agonist GW0742 (0.01, 0.1, or 1.0 μM) or on a background of 2% serum-containing vehicle or PPAR-β/δ antagonist GSK0660 (0.01, 0.1, or 1.0 μM) for 6 hours. Cells were washed twice with cold PBS and total RNA was collected. Total RNA isolated from the culture wells was reverse transcribed. Quantitative RT-PCR was performed.
  • 动物实验: Animal Models: Sprague-Dawley rat Dosages: 0.2 or 1.0 mg/kg Administration: i.p.
  • 参考文献:
    1. Shearer BG, et al. Identification and characterization of a selective peroxisome proliferator-activated receptor beta/delta (NR1C2) antagonist. Mol Endocrinol. 2008, 22(2):523-9. 2. Megan E. Capozzi, et al. Peroxisome Proliferator-Activated Receptor-β/δ Regulates Angiogenic Cell Behaviors and Oxygen-Induced Retinopathy. Invest Ophthalmol Vis Sci. 2013, 54(6): 4197–4207.
  • 溶解性: soluble  in  DMSO
  • 保存条件: -20℃
  • 配置溶液浓度参考:
    1mg 5mg 10mg
    1 mM 2.39 ml 11.948 ml 23.896 ml
    5 mM 0.478 ml 2.39 ml 4.779 ml
    10 mM 0.239 ml 1.195 ml 2.39 ml
    50 mM 0.048 ml 0.239 ml 0.478 ml
  • 注意:部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。
输入产品批号:

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:


质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)


  • =
    *
    *


源叶所有产品仅用作科学研究,销售产品行为均适用于我司网上所列通用销售条款。